Recent News

• 06.02.2026 - Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
• 06.01.2026 - Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
• 05.22.2026 - Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
• 05.04.2026 - Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
• 04.27.2026 - Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Recent Filings

• 06.02.2026 - 8-K Current report
• 06.02.2026 - EX-99.1 EX-99.1
• 06.01.2026 - 8-K Current report
• 06.01.2026 - EX-99.1 EX-99.1
• 05.22.2026 - EX-99.1 EX-99.1
• 05.22.2026 - 8-K Current report
• 05.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.04.2026 - 8-K Current report
• 05.04.2026 - EX-99.1 EX-99.1
• 04.27.2026 - EX-99.1 EX-99.1